The Project to Accelerate New Treatments for Tuberculosis (PAN-TB) collaboration announced today the execution of a joint development agreement (JDA) supporting the progression of two investigational tuberculosis (TB) combination treatment regimens into phase 2 clinical development. The collaboration will evaluate whether the novel regimens, which combine registered products and new chemical entities (NCEs), can effectively treat all forms of active pulmonary TB using substantially shorter treatment durations than existing drug regimens, with the goal of identifying a regimen suitable for phase 3 development. Read more here.
top of page
Recent Posts
See AllThis week, the WHO recommended four new treatments for patients with MDR-TB. Three of the regimens were from the End TB trial, and one...
130
The Health Justice Initiative in South Africa has reported that the South African government is utilizing the Competition Act to...
290
Johnson and Johnson successfully applied for a patent extension on bedaquiline; however, in a big win for LMI countries, the company has...
200
bottom of page
Comments